Strong Royalty Receipts growth; Portfolio Receipts growth impacted by a high base of comparison Capital Deployment of $2.8 billion in 2024 with royalties on eight new therapies added to the portfolio Exciting new product launches expected across the royalty portfolio in 2025 • Royalty Pharma to benefit in 2025 from new product launches, including Servier's Voranigo, Bristol Myers Squibb's Cobenfy, Ascendis' Yorvipath, Syndax and Incyte's Niktimvo and Geron's Rytelo. Financial guidance for full year 2025 (ex ...

Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citi Christopher Schott - JPMorgan Chase & Co Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Dina R ...

Core Insights - Royalty Pharma reported $742 million in revenue for Q4 2024, a year-over-year increase of 0.8%, with an EPS of $1.15, matching the previous year's figure [1] - The revenue exceeded the Zacks Consensus Estimate of $725.33 million by 2.30%, and the EPS surpassed the consensus estimate of $1.09 by 5.50% [1] Financial Performance Metrics - The company’s shares returned +5.8% over the past month, outperforming the Zacks S&P 500 composite's +4.2% change, and currently holds a Zacks Rank 3 (Hold) [3] - Total Portfolio Receipts from Royalty Receipts Products amounted to $729 million, exceeding the average estimate of $711.32 million, reflecting a year-over-year increase of +61.5% [4] Product-Specific Performance - Cystic fibrosis franchise generated $237 million, surpassing the average estimate of $219.16 million, with a year-over-year change of +114.4% [4] - Tysabri reported $61 million, slightly above the estimated $60.23 million, marking a +171.1% increase year-over-year [4] - Imbruvica generated $46 million, exceeding the estimate of $45.80 million, with a +180.6% year-over-year change [4] - Xtandi also reported $46 million, surpassing the average estimate of $44.22 million, reflecting a +205.6% increase year-over-year [4] - Promacta generated $44 million, exceeding the estimate of $39.82 million, with a +134.6% year-over-year change [4] - Evrysdi reported $56 million, above the estimate of $53.49 million, marking a +183.5% increase year-over-year [4] - Trodelvy generated $11 million, slightly below the estimate of $11.66 million, with a +119.5% year-over-year change [4] - Trelegy reported $74 million, exceeding the average estimate of $72.55 million, reflecting a +23% year-over-year change [4]

Exhibit 99.1 ROYALTY PHARMA TO HIGHLIGHT ACCOMPLISHMENTS AND PROVIDE BUSINESS UPDATE AT 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE NEW YORK, NY, January 10, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2024 outlook for Portfolio Receipts. Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer, will discuss these updates on January 14, 2025 as part of a webcast presentation to be held a ...

Core Insights - Royalty Pharma plc reported strong financial results for Q4 and full year 2024, with double-digit growth in Royalty Receipts and a significant capital deployment of $2.8 billion on royalties [2][7][21] - The company anticipates continued growth in 2025, with Portfolio Receipts expected to be between $2,900 million and $3,050 million, reflecting a growth rate of 4% to 9% [5][29] - Royalty Pharma has initiated a $3 billion share repurchase program and acquired its external manager, which is expected to enhance shareholder value and reduce costs [2][15][22] Financial Performance - Q4 2024 Portfolio Receipts were $742 million, a 1% increase from Q4 2023, while full year 2024 Portfolio Receipts decreased by 8% to $2,801 million [6][12][58] - Royalty Receipts grew by 12% in Q4 2024 to $729 million and by 13% for the full year to $2,771 million, driven by strong performances from key products [8][11][59] - Adjusted EBITDA for Q4 2024 was $669 million, a 2% decrease from the previous year, while full year Adjusted EBITDA was $2,565 million, down 9% [19][49] Capital Deployment and Investments - The company deployed $2.8 billion in capital during 2024, acquiring royalties on eight new therapies, and expects to benefit from new product launches in 2025 [4][17][21] - Royalty Pharma's liquidity position as of December 31, 2024, included cash and cash equivalents of $929 million and total debt of $7.8 billion [13][51] - The company repurchased approximately 8 million Class A ordinary shares for $230 million in 2024, with plans for further repurchases in 2025 [14][15] Strategic Initiatives - The acquisition of RP Management, LLC is expected to generate significant cost savings and enhance shareholder alignment, with projected savings exceeding $1.6 billion over ten years [22][23] - Royalty Pharma's transaction pipeline remains robust, with a focus on value-enhancing royalty acquisitions [2][4] - The company has a disciplined capital allocation strategy, bolstered by recent cash proceeds from the sale of MorphoSys Development Funding Bonds [20]

Transaction Overview - Royalty Pharma closed a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash, resulting in total cash proceeds of $530 million on the original $300 million investment made in September 2022 [1] - The company achieved an attractive return by monetizing future fixed payments at a low discount rate of 5.35% and plans to redeploy the proceeds into higher-returning investment opportunities, including share repurchases and acquiring new royalties [1][8] Strategic Context - The monetization was driven by Novartis' acquisition of MorphoSys, which created a unique opportunity to convert fixed long-term payments into a large cash inflow at an attractive return for shareholders [2] - Royalty Pharma updated its capital allocation framework earlier in the year, aiming to generate attractive returns through a blend of royalty investments and share repurchases, enhancing flexibility for disciplined capital allocation [2] Transaction Details - Royalty Pharma entered a long-term strategic funding partnership with MorphoSys in 2021, providing up to $2.025 billion for MorphoSys' acquisition of Constellation Pharmaceuticals, acquiring royalties on Tremfya and other development-stage assets [3] - Prior to the monetization, Royalty Pharma received two quarterly repayments on the Development Funding Bonds, totaling $19.4 million ($9.7 million in Q4 2024 and $9.7 million in January 2025), which will be recorded in Portfolio Receipts [4] - The $511 million monetization proceeds will be treated as an asset sale and not recorded as Portfolio Receipts, and Royalty Pharma will no longer receive Development Funding Bond payments after this transaction [4] Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, collaborating with academic institutions, research hospitals, and companies of all sizes [6] - The company's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and Johnson & Johnson's Tremfya, as well as 14 development-stage product candidates [6] Financial Impact - The total proceeds of $530 million on the original $300 million investment strengthen the company's balance sheet and provide added flexibility to pursue its disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions [8]

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call informa ...

Shares of Royalty Pharma (RPRX) have gained 23.4% over the past four weeks to close the last trading session at $30.75, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.33 indicates a potential upside of 31.2%.The average comprises six short-term price targets ranging from a low of $28 to a high of $51, with a standard deviation of $7.39. While the lowest estimate indicates a ...

Stock Performance - Royalty Pharma plc (NASDAQ: RPRX) stock price increased by more than 16% following a Strong Buy suggestion in early November 2024, outperforming the S&P 500 change [1] Analyst Position - The analyst has a beneficial long position in RPRX shares through stock ownership, options, or other derivatives [2] Disclosure Information - The article expresses the analyst's own opinions and is not receiving compensation other than from Seeking Alpha [2] - Seeking Alpha's analysts are third-party authors, including both professional and individual investors, who may not be licensed or certified by any institute or regulatory body [3]

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 200-day moving average, suggesting a long-term bullish trend.A useful tool for traders and analysts, the 200-day simple moving average helps determine long-term market trends for stocks, commodities, indexes, and other financial instruments. It moves higher or lower in conjunction with longer-term price performance, and serves as a support or ...